Literature DB >> 24367024

B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system.

Emily R Pierson1, Ingunn M Stromnes, Joan M Goverman.   

Abstract

The efficacy of rituximab treatment in multiple sclerosis has renewed interest in the role of B cells in CNS autoimmunity. In this study, we show that B cells are the predominant MHC class II(+) subset in the naive CNS in mice, and they constitutively express proinflammatory cytokines. Incidence of experimental autoimmune encephalomyelitis induced by adoptive transfer was significantly reduced in C3HeB/Fej μMT (B cell-deficient) mice, suggesting an important role for CNS B cells in initiating inflammatory responses. Initial T cell infiltration of the CNS occurred normally in μMT mice; however, lack of production of T cell cytokines and other immune mediators indicated impaired T cell reactivation. Subsequent recruitment of immune cells from the periphery driven by this initial T cell reactivation did not occur in μMT mice. B cells required exogenous IL-1β to reactivate Th17 but not Th1 cells in vitro. Similarly, reactivation of Th1 cells infiltrating the CNS was selectively impaired compared with Th17 cells in μMT mice, causing an increased Th17/Th1 ratio in the CNS at experimental autoimmune encephalomyelitis onset and enhanced brain inflammation. These studies reveal an important role for B cells within the CNS in reactivating T cells and influencing the clinical manifestation of disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24367024      PMCID: PMC3934009          DOI: 10.4049/jimmunol.1302171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

2.  Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity.

Authors:  Gregory F Wu; Kenneth S Shindler; Eric J Allenspach; Tom L Stephen; Hannah L Thomas; Robert J Mikesell; Anne H Cross; Terri M Laufer
Journal:  J Autoimmun       Date:  2010-11-20       Impact factor: 7.094

3.  Conditional DC depletion does not affect priming of encephalitogenic Th cells in EAE.

Authors:  Magnus Isaksson; Brita Ardesjö Lundgren; Kerstin M Ahlgren; Olle Kämpe; Anna Lobell
Journal:  Eur J Immunol       Date:  2012-08-08       Impact factor: 5.532

4.  Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

Authors:  Amit Bar-Or; Lama Fawaz; Boli Fan; Peter J Darlington; Aja Rieger; Christine Ghorayeb; Peter A Calabresi; Emmanuelle Waubant; Stephen L Hauser; Jiameng Zhang; Craig H Smith
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

5.  B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide.

Authors:  J A Lyons; M San; M P Happ; A H Cross
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

Review 6.  The role of antibodies in multiple sclerosis.

Authors:  Martin S Weber; Bernhard Hemmer; Sabine Cepok
Journal:  Biochim Biophys Acta       Date:  2010-06-25

7.  Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.

Authors:  Nir Yogev; Friederike Frommer; Dominika Lukas; Kordula Kautz-Neu; Khalad Karram; Daniele Ielo; Esther von Stebut; Hans-Christian Probst; Maries van den Broek; Dieter Riethmacher; Tal Birnberg; Thomas Blank; Boris Reizis; Thomas Korn; Heinz Wiendl; Steffen Jung; Marco Prinz; Florian C Kurschus; Ari Waisman
Journal:  Immunity       Date:  2012-08-16       Impact factor: 31.745

8.  Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.

Authors:  Amit Bar-Or; Peter A J Calabresi; Douglas Arnold; Douglas Arnlod; Clyde Markowitz; Stuart Shafer; Lloyd H Kasper; Emmanuelle Waubant; Suzanne Gazda; Robert J Fox; Michael Panzara; Neena Sarkar; Sunil Agarwal; Craig H Smith
Journal:  Ann Neurol       Date:  2008-03       Impact factor: 10.422

9.  Cutting edge: Conditional MHC class II expression reveals a limited role for B cell antigen presentation in primary and secondary CD4 T cell responses.

Authors:  Angela S Archambault; Javier A Carrero; Lisa G Barnett; Nigel G McGee; Julia Sim; Jonathan O Wright; Tobias Raabe; Peiquin Chen; Hua Ding; Eric J Allenspach; Ioannis Dragatsis; Terri M Laufer; Gregory F Wu
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

10.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.

Authors:  Tom A Barr; Ping Shen; Sheila Brown; Vicky Lampropoulou; Toralf Roch; Sarah Lawrie; Boli Fan; Richard A O'Connor; Stephen M Anderton; Amit Bar-Or; Simon Fillatreau; David Gray
Journal:  J Exp Med       Date:  2012-04-30       Impact factor: 14.307

View more
  42 in total

Review 1.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

Review 2.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 3.  Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity.

Authors:  Ari Waisman; Lisa Johann
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

4.  Aged hind-limb clasping experimental autoimmune encephalomyelitis models aspects of the neurodegenerative process seen in multiple sclerosis.

Authors:  Lindsay S Cahill; Monan Angela Zhang; Valeria Ramaglia; Heather Whetstone; Melika Pahlevan Sabbagh; Tae Joon Yi; Laura Woo; Thomas S Przybycien; Marina Moshkova; Fei Linda Zhao; Olga L Rojas; Josephine Gomes; Stefanie Kuerten; Jennifer L Gommerman; John G Sled; Shannon E Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-22       Impact factor: 11.205

5.  B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease.

Authors:  Emanuel Della-Torre; Eoin Feeney; Vikram Deshpande; Hamid Mattoo; Vinay Mahajan; Maria Kulikova; Zachary S Wallace; Mollie Carruthers; Raymond T Chung; Shiv Pillai; John H Stone
Journal:  Ann Rheum Dis       Date:  2014-08-20       Impact factor: 19.103

6.  Design of biodegradable nanoparticles to modulate phenotypes of antigen-presenting cells for antigen-specific treatment of autoimmune disease.

Authors:  Eiji Saito; Robert Kuo; Kevin R Kramer; Nishant Gohel; David A Giles; Bethany B Moore; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2019-08-17       Impact factor: 12.479

7.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

Review 8.  Regulatory T cells and minimal change nephropathy: in the midst of a complex network.

Authors:  R Bertelli; A Bonanni; A Di Donato; M Cioni; P Ravani; G M Ghiggeri
Journal:  Clin Exp Immunol       Date:  2015-10-12       Impact factor: 4.330

9.  Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy.

Authors:  Ari Waisman; Anna Ebering
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

Review 10.  T cell responses in the central nervous system.

Authors:  Thomas Korn; Axel Kallies
Journal:  Nat Rev Immunol       Date:  2017-01-31       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.